Macquarie Group
SYRS

Macquarie Group’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History

Macquarie Group’s Portfolio SYRS Stock Details SYRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-613
Closed -$3 – 2181
2024
Q1 		$3 Buy
+613
New +$4.24K ﹤0.01% 1841
2018
Q1 		– Sell
-90
Closed -$9K – 2397
2017
Q4 		$9K Buy
+90
New +$12.1K ﹤0.01% 2285

Other funds holding SYRS

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Macquarie Group's SYRS Position: Q2 2024 in Review

Macquarie Group sold out of Syros Pharmaceuticals, Inc. Common Stock (SYRS) in Q2 2024, closing a stake of 613 shares — an estimated $3 sold.

Macquarie Group first reported a position in SYRS in Q4 2017 and held it in 2 quarters. The position peaked at $9K in Q4 2017. 70 funds tracked by Wall St. Rank hold SYRS as of Q2 2024.

  • Macquarie Group reported no remaining Syros Pharmaceuticals, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
  • Macquarie Group sold 613 Syros Pharmaceuticals, Inc. Common Stock shares in Q2 2024, an estimated $3.
  • Macquarie Group first reported a position in Syros Pharmaceuticals, Inc. Common Stock in Q4 2017 and held it in 2 quarters.
  • Macquarie Group's Syros Pharmaceuticals, Inc. Common Stock position peaked at $9K in Q4 2017.
  • 70 funds tracked by Wall St. Rank held Syros Pharmaceuticals, Inc. Common Stock as of Q2 2024.

Based on Macquarie Group's 13F filing for Q2 2024, filed 9 Aug 2024.